Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
itching at the injection site; redness at the injection site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site itching in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced injection site itching (Verbatim: itching at the injection site) and injection site erythema (Verbatim: redness at the injection site). The outcome of the injection site itching and injection site erythema were not reported. It was unknown if the reporter considered the injection site itching and injection site erythema to be related to Shingles vaccine. It was unknown if the company considered the injection site itching and injection site erythema to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 31-MAY-2025 This case was reported by a patient via (Shingrix chatbot) interactive digital media. Reporter asked whether it was normal to experience itching and redness at the injection site.